NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Accelerating Access to Latin America Innovative Therapies Through Collaborati...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line The...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...